Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.02873
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Natural Killer (NK) Cells Engineered to Target Tumors

Science-Business eXchange
2008English

High-Affinity CD16-polymorphism and Fc-Engineered Antibodies Enable Activity of CD16-chimeric Antigen Receptor-Modified T Cells for Cancer Therapy

British Journal of Cancer
Cancer ResearchOncology
2018English

Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells

Clinical Cancer Research
Cancer ResearchOncology
2009English

Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma

Clinical Medicine Insights: Oncology
Oncology
2015English

miR-133 Regulates Evi1 Expression in AML Cells as a Potential Therapeutic Target

Scientific Reports
Multidisciplinary
2016English

Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2017English

Engineered Red Blood Cells as Therapeutic Agents

American Journal of Hematology
Hematology
2017English

Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster

Frontiers in Immunology
AllergyImmunology
2019English

Dynamics of the Interaction of Human IgG Subtype Immune Complexes With Cells Expressing R and H Allelic Forms of a Low-Affinity Fc Receptor CD32A

Journal of Immunology
AllergyImmunology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy